The U.S. Environmental Protection Agency (EPA) has proposed sweeping regulations that would require states to reduce carbon dioxide emissions from the electricity sector by an average of 30 percent nationally. This costly plan is another step in the administration's policies designed to eliminate low cost and reliable electricity and replace it with more expensive and less reliable sources.
"The rule is a stunning attempt to remake the nation's entire electric grid at great cost to households and businesses across the US. Our manufacturing base will become less competitive because of higher electricity prices. The impact of this regulation will be felt by families as they will spend more to heat and cool their homes. Those on fixed incomes and seniors will be forced to pay a disproportionately higher share of their monthly budget on utilities," said Hal Quinn, president and CEO, National Mining Association."
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221731-national-mining-association-americans-electricity-bill-increase-due-to-epa-regulations/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
The American Coalition for Clean Coal Electricity today released a new report “Energy Cost Impacts on Families” that details the plight of American households who are significantly harmed by rising energy costs.
The study finds that on average nearly half of America’s households are bringing home $1,900 a month, less than $23,000 annually, and spending 17 percent of those hard-earned dollars on energy. Low and fixed income families, including minorities and senior citizens, are among the most vulnerable to energy price increases and frequently must make tough choices about what to do to meet energy costs.
“No one should go without food or medication to keep the lights on but that’s exactly what is taking place in millions of households across America,” said Mike Duncan, president and CEO of ACCCE. “Regulations like EPA’s calamitous Clean Power Plan will only exacerbate the economic struggles families face, making it all that much harder to keep a roof over their heads and food on the table. This administration should put Americans ahead of its politically charged agenda and immediately take action to ensure vulnerable families are not harmed further by these reckless regulations.”
To view the Multimedia News Release, go http://www.multivu.com/players/English/7552751-accce-family-energy-impact-report/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces today its latest innovation, the Cochlear™ Nucleus® 7 Sound Processor. Approved by the U.S. Food and Drug Administration (FDA) in June, the Nucleus 7 Sound Processor is the world’s first Made for iPhone cochlear implant sound processor and the smallest and lightest behind-the-ear cochlear implant sound processor available on the market.1-3
With the Nucleus 7 Sound Processor, people with a Cochlear Nucleus Implant can now stream sound directly from a compatible iPhone, iPad and iPod touch directly to their sound processor.4,5* They will also be able to control, monitor and customize their hearing on their iPhone or iPod touch through the Nucleus® Smart App available to download for free from the App Store®.
To view the multimedia release go to:
https://www.multivu.com/players/English/7987851-cochlear-nucleus-7-sound-processor/
The winter of 2016-2017 is in its early stages, and yet many parts of the country are already experiencing extreme weather conditions and power outages. In fact, a power outage can happen at any time, and it can affect the safety of your food. The U.S. Food and Drug Administration reminds you that the best way to ensure that food stays safe is to have a plan in place, and to know what food safety precautions to take if a power outage does occur.
To view the multimedia release go to:
http://www.multivu.com/players/English/7876851-fda-power-outage-food-safety-2016/
The 1-year Full-Time MBA is the School’s flagship program with just about 100 MBA students. It is a challenging life time experience to learn the art of management and grow personally and professionally.
Full-Time MBA structure is organized around three cornerstones: Planning and Innovating, Controlling and Investing, Leading People and Processes. These core courses represent the competence requirements of a global manager.
To view the Multimedia News Release, go to http://www.multivu.com/players/uk/7674251-sda-bocconi-1-year-full-time-mba/
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
